Biljana Horn, MD - Research

Research at a glance

Top areas of exploration

Hematopoietic Stem Cell Transplantation , 34 publications
Graft vs Host Disease , 12 publications
Transplantation Conditioning , 11 publications
Transplantation, Homologous , 10 publications

Research activity

60 publications

1,620 citations

Why is this important?

Active clinical trials

BMT12108, Non-Myeloablative Conditioning and Bone Marrow Transplantation

Allogeneic blood or marrow transplantation (alloBMT) is a curative therapy for a variety of hematologic disorders, including sickle cell disease and thalassemia. Even when it is clear that alloBMT can give to these patients an improvement in their鈥�

Investigators: Jordan Milner, Biljana Horn
Status: Accepting Candidates
Ages: 1 Year - 70 Years
Sexes: All

Conditioning SCID Infants Diagnosed Early (CSIDE)

The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune鈥�

Investigators: Jordan Milner, Biljana Horn
Status: Accepting Candidates
Ages: 0 Years - 2 Years
Sexes: All

My publications

60 publications

2017

Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients.

Journal of neuro-oncology

鈥�

2017

Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency.

The Journal of allergy and clinical immunology

鈥�

2015

Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

鈥�

2015

Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.

Therapeutic drug monitoring

鈥�

2014

A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.

Pediatric transplantation

鈥�

网红黑料